Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.39 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136627 | 1.00 | AURKA (0.51) | AURKARPS6KB1TOP2ATOP2BTLR7 | |
| SCHEMBL29136634 | 0.90 | AURKA (0.48) | AURKARPS6KB1TOP2ATOP2BMMP1 | |
| SCHEMBL29947686 | 0.90 | AURKA (0.48) | AURKARPS6KB1TOP2ATOP2BMMP1 | |
| SCHEMBL26981143 | 0.86 | PDE5A (0.45) | METLMNAMAPTGRM5SENP5 | |
| SCHEMBL29947712 | 0.85 | AURKA (0.56) | AURKARPS6KB1TOP2ATOP2BTLR7 | |
| SCHEMBL29136646 | 0.85 | AURKA (0.56) | AURKARPS6KB1TOP2ATOP2BTLR7 | |
| SCHEMBL29947704 | 0.85 | EGFR (0.44) | BRD4LMNAMAPTGRM5 | |
| SCHEMBL29136628 | 0.85 | EGFR (0.44) | BRD4LMNAMAPTGRM5 | |
| SCHEMBL12757193 | 0.80 | MEN1 (0.45) | TOP2ATOP2BMETLMNAMAPT | |
| SCHEMBL1041911 | 0.80 | MEN1 (0.45) | TOP2ATOP2BMETLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | AURKA 4094/4885RPS6KB1 328/4885TOP2A 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.